Table 1

Baseline characteristics of HCV negative and positive individuals in the overall study population and the propensity score (PS)-matched dataset, from the British Columbia Hepatitis Testers Cohort 1990–2015

CovariateOverall study populationPS-matched dataset*
HCV negative
(n=785 451)
HCV positive (n=61 570)SMDHCV negative
(n=58 592)
HCV positive (n=58 592)SMD
Sex (%)0.4130.014
 Female434 731 (55.3)21 694 (35.2)21 054 (35.9)20 665 (35.3)
 Male350 720 (44.7)39 876 (64.8)37 927 (64.7)37 538 (64.1)
Age at HCV diagnosis (%)0.4390.037
 <25122 524 (15.6)4409 (7.2)4485 (7.7)4326 (7.4)
 25–34196 472 (25.0)13 485 (21.9)12 109 (20.7)12 749 (21.8)
 35–44172 656 (22.0)20 088 (32.6)18 302 (31.2)18 674 (31.9)
 45–54125 087 (15.9)15 300 (24.8)15 032 (25.7)14 604 (24.9)
 ≥55168 712 (21.5)8288 (13.5)8664 (14.8)8239 (14.1)
Follow-up duration, mean years (SD)7.50 (5.4)11.59 (6.4)0.68711.24 (5.97)11.42 (6.42)0.029
Ethnicity (%)0.3600.241
 Other†656 110 (83.5)58 137 (94.4)51 401 (87.7)55 197 (94.2)
 East Asian78 135 (9.9)1618 (2.6)4465 (7.6)1602 (2.7)
 South Asian51 206 (6.5)1815 (2.9)2726 (4.7)1793 (3.1)
Material DQ (%)0.3530.009
 Q1 (most privileged)175 410 (22.3)8242 (13.4)8004 (13.7)8052 (13.7)
 Q2154 413 (19.7)9764 (15.9)9357 (16.0)9445 (16.1)
 Q3157 151 (20.0)10 946 (17.8)10 443 (17.8)10 567 (18.0)
 Q4157 680 (20.1)14 117 (22.9)13 491 (23.0)13 432 (22.9)
 Q5 (most deprived)140 797 (17.9)18 501 (30.0)17 297 (29.5)17 096 (29.2)
Social DQ (%)0.3620.009
 Q1 (most privileged)141 254 (18.0)6321 (10.3)6303 (10.8)6236 (10.6)
 Q2139 115 (17.7)7726 (12.5)7538 (12.9)7560 (12.9)
 Q3143 967 (18.3)10 167 (16.5)9720 (16.6)9826 (16.8)
 Q4164 587 (21.0)13 022 (21.1)12 387 (21.1)12 503 (21.3)
 Q5 (most deprived)196 528 (25.0)24 334 (39.5)22 644 (38.6)22 467 (38.3)
HBV infection (%)10 781 (1.4)947 (1.5)0.014744 (1.3)821 (1.4)0.011
HIV infection (%)1596 (0.2)1676 (2.7)0.211917 (1.6)939 (1.6)0.003
Cirrhosis (%)4919 (0.6)877 (1.4)0.079514 (0.9)817 (1.4)0.049
CKD (%)14 995 (1.9)532 (0.9)0.089801 (1.4)497 (0.8)0.050
ESRD (%)5490 (0.7)356 (0.6)0.015405 (0.7)304 (0.5)0.022
IHD (%)36 799 (4.7)1572 (2.6)0.1142430 (4.1)1518 (2.6)0.086
Hypertension (%)105 284 (13.4)4224 (6.9)0.2186359 (10.9)4090 (7.0)0.136
Statin use (%)52 698 (6.7)1170 (1.9)0.2393149 (5.4)1142 (1.9)0.183
Mood and anxiety disorder (%)270 332 (34.4)23 440 (38.1)0.07622 159 (37.8)21 594 (36.9)0.020
Obesity (%)19 043 (2.4)967 (1.6)0.061990 (1.7)950 (1.6)0.005
Alcohol use disorder (%)30 368 (3.9)10 286 (16.7)0.4328943 (15.3)8458 (14.4)0.023
Injection drug use (%)18 789 (2.4)11 172 (18.1)0.5378780 (15.0)8529 (14.6)0.012
  • *The propensity score (PS)-matched dataset was created by matching individuals with HCV infection with individuals without infection with a caliper of 0.1 at a 1:1 ratio without replacement. PS was estimated based on age at HCV diagnosis, duration of follow-up, sex, material/social deprivation quintiles, HBV/HIV infection, mood and anxiety disorders, obesity, alcohol use disorder and injection drug use.

  • †Other included white, Indigenous, black, Latin American, Pacific Islander, Central/West Asian, Filipino, Southeast Asian and other residents of British Columbia.

  • CKD, chronic kidney disease; DQ, deprivation quintiles; ESRD, end-stage renal disease; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IHD, ischemic heart disease; PS, propensity scores; Q, quintile; SD, standard deviation; SMD, standardized mean difference.